AstraZeneca PLC's tozorakimab may have missed its primary goal in a mid-stage trial but the UK major remains confident that the IL-33 monoclonal antibody is a potential best-in-class candidate for chronic obstructive pulmonary disease (COPD).
AstraZeneca's Hopes Still High For Tozorakimab In COPD
The company's IL-33 drug failed to improve breathing in a chronic obstructive pulmonary disease Phase II trial but benefited patients who had suffered moderate or severe exacerbations in the previous year.
